C5a stimulates the proliferation of breast cancer cells via Akt-dependent RGC-32 gene activation

Lu,Yi; Hu,Xiao-Bo

doi:10.3892/or.2014.3489

C5a stimulates the proliferation of breast cancer cells via Akt-dependent RGC-32 gene activation

Authors:
- Yi Lu
- Xiao-Bo Hu
View Affiliations

Affiliations: Department of General Surgery, Suzhou Kowloon Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, Suzhou, Jiangsu 215021, P.R. China, Department of Breast Surgery, The Affiliated Tumor Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, P.R. China
Published online on: September 17, 2014 https://doi.org/10.3892/or.2014.3489
Pages: 2817-2823

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Complement system activation contributes to various immune and inflammatory diseases, as well as cancers.However, the role of complement activation in the proliferation of cancer cells is not clear. In the present study, we investigated the consequences of complement activation on the proliferation of breast cancer cells and its possible mechanisms. We focused our study on the potential roles of the anaphylatoxins C3a and C5a in the proliferation of human breast cancer, as two important immune mediators generated after complement activation. Our study revealed that C5a stimulation, but not C3a, enhanced the proliferation of human breast cancer cells in vitro. Moreover, the expression of response gene to complement 32 (RGC-32) was pronounced in breast cancer cells in response to C5a stimulation. Notably, blockade of the C5a receptor markedly reduced the expression of RGC-32 and the proliferation of breast cancer cells stimulated by C5a. Meanwhile, silencing of RGC-32 expression reduced the proliferation of breast cancer cells induced by C5a treatment. Further investigation revealed that Akt activation was involved in C5a-induced RGC-32 expression and breast cancer cell proliferation. In conclusion, the present study indicates that C5a may promote the proliferation of breast cancer cells through Akt1 activation of the RGC-32 gene.

View Figures

View References

1	Tong HH, Lambert G, Li YX, et al: Deletion of the complement C5a receptor alleviates the severity of acute pneumococcal otitis media following influenza A virus infection in mice. PloS One. 9:e951602014. View Article : Google Scholar : PubMed/NCBI
2	Courtois A, Berthou C, Guezennec J, Boisset C and Bordron A: Exopolysaccharides isolated from hydrothermal vent bacteria can modulate the complement system. PloS One. 9:e949652014. View Article : Google Scholar : PubMed/NCBI
3	Wende E, Laudeley R, Bleich A, et al: The complement anaphylatoxin C3a receptor (C3aR) contributes to the inflammatory response in dextran sulfate sodium (DSS)-induced colitis in mice. PloS One. 8:e622572013. View Article : Google Scholar : PubMed/NCBI
4	Elvington M, Blichmann P, Qiao F, et al: A novel protocol allowing oral delivery of a protein complement inhibitor that subsequently targets to inflamed colon mucosa and ameliorates murine colitis. Clin Exp Immunol. 500–508. 2014. View Article : Google Scholar
5	Hundgeburth LC, Wunsch M, Rovituso D, et al: The complement system contributes to the pathology of experimental autoimmune encephalomyelitis by triggering demyelination and modifying the antigen-specific T and B cell response. Clin Immunol. 146:155–164. 2013. View Article : Google Scholar
6	Laudisi F, Spreafico R, Evrard M, et al: Cutting edge: the NLRP3 inflammasome links complement-mediated inflammation and IL-1β release. J Immunol. 191:1006–1010. 2013.PubMed/NCBI
7	Ma R, Cui Z, Hu SY, et al: The alternative pathway of complement activation may be involved in the renal damage of human anti-glomerular basement membrane disease. PloS One. 9:e912502014. View Article : Google Scholar : PubMed/NCBI
8	Osthoff M, Brown KD, Kong DC, Daniell M and Eisen DP: Activation of the lectin pathway of complement in experimental human keratitis with Pseudomonas aeruginosa. Mol Vis. 20:38–45. 2014.PubMed/NCBI
9	Cravedi P, Leventhal J, Lakhani P, Ward SC, Donovan MJ and Heeger PS: Immune cell-derived C3a and C5a costimulate human T cell alloimmunity. Am J Transplant. 13:2530–2539. 2013. View Article : Google Scholar : PubMed/NCBI
10	van der Touw W, Cravedi P, Kwan WH, Paz-Artal E, Merad M and Heeger PS: Cutting edge: Receptors for C3a and C5a modulate stability of alloantigen-reactive induced regulatory T cells. J Immunol. 190:5921–5925. 2013.PubMed/NCBI
11	Lara-Astiaso D, Izarra A, Estrada JC, et al: Complement anaphylatoxins C3a and C5a induce a failing regenerative program in cardiac resident cells. Evidence of a role for cardiac resident stem cells other than cardiomyocyte renewal. Springerplus. 1:632012. View Article : Google Scholar
12	Kanmura S, Uto H, Sato Y, et al: The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol. 45:459–467. 2010. View Article : Google Scholar : PubMed/NCBI
13	Habermann JK, Roblick UJ, Luke BT, et al: Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology. 131:1020–1029. 2006. View Article : Google Scholar : PubMed/NCBI
14	Stecker JR, Savage AA, Bruno JG, Garcia DM and Koke JR: Dynamics and visualization of MCF7 adenocarcinoma cell death by aptamer-C1q-mediated membrane attack. Nucleic Acid Ther. 22:275–282. 2012.PubMed/NCBI
15	Baig NA, Taylor RP, Lindorfer MA, et al: Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement. Leuk Lymphoma. 53:2218–2227. 2012. View Article : Google Scholar
16	Nitta H, Wada Y, Kawano Y, et al: Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88). Clin Cancer Res. 19:2004–2013. 2013. View Article : Google Scholar : PubMed/NCBI
17	Corrales L, Ajona D, Rafail S, et al: Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol. 189:4674–4683. 2012. View Article : Google Scholar : PubMed/NCBI
18	Fosbrink M, Cudrici C, Tegla CA, et al: Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cells. Exp Mol Pathol. 86:87–94. 2009. View Article : Google Scholar : PubMed/NCBI
19	Vlaicu SI, Cudrici C, Ito T, et al: Role of response gene to complement 32 in diseases. Arch Immunol Ther Exp. 56:115–122. 2008. View Article : Google Scholar : PubMed/NCBI
20	Badea TC, Niculescu FI, Soane L, Shin ML and Rus H: Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes. J Biol Chem. 273:26977–26981. 1998. View Article : Google Scholar : PubMed/NCBI
21	Vlaicu SI, Tegla CA, Cudrici CD, et al: Epigenetic modifications induced by RGC-32 in colon cancer. Exp Mol Pathol. 88:67–76. 2010. View Article : Google Scholar : PubMed/NCBI
22	Li F, Luo Z, Huang W, et al: Response gene to complement 32, a novel regulator for transforming growth factor-beta-induced smooth muscle differentiation of neural crest cells. J Biol Chem. 282:10133–10137. 2007. View Article : Google Scholar : PubMed/NCBI
23	Zhu L, Qin H, Li PY, et al: Response gene to complement-32 enhances metastatic phenotype by mediating transforming growth factor beta-induced epithelial-mesenchymal transition in human pancreatic cancer cell line BxPC-3. J Exp Clin Cancer Res. 31:292012. View Article : Google Scholar
24	Yunus MA, Chung LM, Chaudhry Y, Bailey D and Goodfellow I: Development of an optimized RNA-based murine norovirus reverse genetics system. J Virol Methods. 169:112–118. 2010. View Article : Google Scholar : PubMed/NCBI
25	Li M, Han S, Zhang G, Wang Y and Ji Z: Antiproliferative activity and apoptosis-inducing mechanism of L-securinine on human breast cancer MCF-7 cells. Pharmazie. 69:217–223. 2014.PubMed/NCBI
26	Gong S, Tao Z, Liu X and Gan L: An underlying prognosis predictor of hepatocellular carcinoma: Oncoprotein 18. Biomed Rep. 2:85–88. 2014.PubMed/NCBI
27	Qiu W, Zhang Y, Liu X, et al: Sublytic C5b-9 complexes induce proliferative changes of glomerular mesangial cells in rat Thy-1 nephritis through TRAF6-mediated PI3K-dependent Akt1 activation. J Pathol. 226:619–632. 2012. View Article : Google Scholar : PubMed/NCBI
28	Tang H, Amara U, Tang D, Barnes MA, McDonald C and Nagy LE: Synergistic interaction between C5a and NOD2 signaling in the regulation of chemokine expression in RAW 264.7 macrophages. Adv Biosci Biotechnol. 4:30–37. 2013. View Article : Google Scholar : PubMed/NCBI
29	Curci C, Castellano G, Stasi A, et al: Endothelial-to-mesenchymal transition and renal fibrosis in ischaemia/reperfusion injury are mediated by complement anaphylatoxins and Akt pathway. Nephrol Dial Transplant. 29:799–808. 2014. View Article : Google Scholar : PubMed/NCBI
30	Byler S, Goldgar S, Heerboth S, et al: Genetic and epigenetic aspects of breast cancer progression and therapy. Anticancer Res. 34:1071–1077. 2014.PubMed/NCBI
31	Faria JA, Correa NC, de Andrade C, et al: SET domain-containing protein 4 (SETD4) is a newly identified cytosolic and nuclear lysine methyltransferase involved in breast cancer cell proliferation. J Cancer Sci Ther. 5:58–65. 2013.
32	Pei R, Wang P, Zhou Y, et al: Association of BRCA1 K1183R polymorphism with survival in BRCA1/2-negative Chinese familial breast cancer. Clin Lab. 60:47–53. 2014.PubMed/NCBI
33	Unnewehr H, Rittirsch D, Sarma JV, et al: Changes and regulation of the C5a receptor on neutrophils during septic shock in humans. J Immunol. 190:4215–4225. 2013. View Article : Google Scholar : PubMed/NCBI
34	Liu L, Zhang Y, Duan X, et al: C3a, C5a renal expression and their receptors are correlated to severity of IgA nephropathy. J Clin Immunol. 34:224–232. 2014. View Article : Google Scholar : PubMed/NCBI
35	Müller MC, Stroo I, Wouters D, et al: The effect of C1-inhibitor in a murine model of transfusion-related acute lung injury. Vox Sang. 107:71–75. 2014.PubMed/NCBI
36	Qin L, Ren Y, Chen AM, et al: Peroxisome proliferator-activated receptor γ ligands inhibit VEGF-mediated vasculogenic mimicry of prostate cancer through the AKT signaling pathway. Mol Med Rep. 10:276–282. 2014.
37	Singel SM, Cornelius C, Zaganjor E, et al: KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer. Neoplasia. 16:247–256. 2014. View Article : Google Scholar : PubMed/NCBI